189 related articles for article (PubMed ID: 22898035)
21. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.
Yin X; Zhang H; Lundgren K; Wilson L; Burrows F; Shores CG
Int J Cancer; 2010 Mar; 126(5):1216-25. PubMed ID: 19662650
[TBL] [Abstract][Full Text] [Related]
22. Early Evaluation of Response Using
Farag S; Geus-Oei LF; van der Graaf WT; van Coevorden F; Grunhagen D; Reyners AKL; Boonstra PA; Desar I; Gelderblom H; Steeghs N
J Nucl Med; 2018 Feb; 59(2):194-196. PubMed ID: 28970330
[No Abstract] [Full Text] [Related]
23. BIIB021, a novel Hsp90 inhibitor, sensitizes esophageal squamous cell carcinoma to radiation.
Wang XT; Bao CH; Jia YB; Wang N; Ma W; Liu F; Wang C; Wang JB; Song QX; Cheng YF
Biochem Biophys Res Commun; 2014 Oct; 452(4):945-50. PubMed ID: 25223594
[TBL] [Abstract][Full Text] [Related]
24. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
[TBL] [Abstract][Full Text] [Related]
25. An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors.
Dakappagari N; Neely L; Tangri S; Lundgren K; Hipolito L; Estrellado A; Burrows F; Zhang H
Biomarkers; 2010 Feb; 15(1):31-8. PubMed ID: 19747088
[TBL] [Abstract][Full Text] [Related]
26. BIIB021: A novel inhibitor to heat shock protein 90-addicted oncology.
Yan L; Zhang W; Zhang B; Xuan C; Wang D
Tumour Biol; 2017 Apr; 39(4):1010428317698355. PubMed ID: 28443462
[TBL] [Abstract][Full Text] [Related]
27. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study.
Joensuu H; De Braud F; Grignagni G; De Pas T; Spitalieri G; Coco P; Spreafico C; Boselli S; Toffalorio F; Bono P; Jalava T; Kappeler C; Aglietta M; Laurent D; Casali PG
Br J Cancer; 2011 May; 104(11):1686-90. PubMed ID: 21540861
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07).
Montemurro M; Cioffi A; Dômont J; Rutkowski P; Roth AD; von Moos R; Inauen R; Toulmonde M; Burkhard RO; Knuesli C; Bauer S; Cassier P; Schwarb H; Le Cesne A; Koeberle D; Bärtschi D; Dietrich D; Biaggi C; Prior J; Leyvraz S
Cancer; 2018 Apr; 124(7):1449-1454. PubMed ID: 29315500
[TBL] [Abstract][Full Text] [Related]
29. First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors.
Shapiro GI; Kwak E; Dezube BJ; Yule M; Ayrton J; Lyons J; Mahadevan D
Clin Cancer Res; 2015 Jan; 21(1):87-97. PubMed ID: 25336693
[TBL] [Abstract][Full Text] [Related]
30. Mixed response on regorafenib treatment for GIST (gastro-intestinal stromal tumor) according to
Van Weehaeghe D; Gheysens O; Vandecaveye V; Schöffski P; Van Laere K; Deroose CM
BMC Cancer; 2018 Mar; 18(1):253. PubMed ID: 29506493
[TBL] [Abstract][Full Text] [Related]
31. Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study.
Fuster D; Ayuso JR; Poveda A; Cubedo R; Casado A; Martínez-Trufero J; López-Pousa A; Del Muro XG; Lomeña F; Maurel J; Pons F
Q J Nucl Med Mol Imaging; 2011 Dec; 55(6):680-7. PubMed ID: 21150863
[TBL] [Abstract][Full Text] [Related]
32. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
Choi H; Charnsangavej C; Faria SC; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Benjamin RS
J Clin Oncol; 2007 May; 25(13):1753-9. PubMed ID: 17470865
[TBL] [Abstract][Full Text] [Related]
33. Synergistic cytotoxicity of BIIB021 with triptolide through suppression of PI3K/Akt/mTOR and NF-κB signal pathways in thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Biomed Pharmacother; 2016 Oct; 83():22-32. PubMed ID: 27470546
[TBL] [Abstract][Full Text] [Related]
34. BIIB021, a synthetic Hsp90 inhibitor, induces mutant ataxin-1 degradation through the activation of heat shock factor 1.
Ding Y; Adachi H; Katsuno M; Sahashi K; Kondo N; Iida M; Tohnai G; Nakatsuji H; Sobue G
Neuroscience; 2016 Jul; 327():20-31. PubMed ID: 27058144
[TBL] [Abstract][Full Text] [Related]
35. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
36. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
[TBL] [Abstract][Full Text] [Related]
37. PK-PD modeling of individual lesion FDG-PET response to predict overall survival in patients with sunitinib-treated gastrointestinal stromal tumor.
Schindler E; Amantea MA; Karlsson MO; Friberg LE
CPT Pharmacometrics Syst Pharmacol; 2016 Apr; 5(4):173-81. PubMed ID: 27299707
[TBL] [Abstract][Full Text] [Related]
38. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
Goldstein D; Tan BS; Rossleigh M; Haindl W; Walker B; Dixon J
Oncology; 2005; 69(4):326-32. PubMed ID: 16293972
[TBL] [Abstract][Full Text] [Related]
39. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
Floris G; Sciot R; Wozniak A; Van Looy T; Wellens J; Faa G; Normant E; Debiec-Rychter M; Schöffski P
Clin Cancer Res; 2011 Sep; 17(17):5604-14. PubMed ID: 21737509
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]